IMMUcan receives support from the European Union (grant 821558) within the Innovative Medicine Initiative 2 program and from the European Federation of Pharmaceutical Industries.
IMMUcan was started in March 2019 and will end in August 2024.
The IMMUcan consortium is composed by 17 academic organisations from 8 European countries, 1 patient organisation, 1 SME and
9 pharmaceutical companies. IMMUcan is under the leadership
of Merck and EORTC.